Twentyâ fiveâ year trajectories of insulin resistance and pancreatic βâ cell response and diabetes risk in nonalcoholic fatty liver disease
dc.contributor.author | VanWagner, Lisa B. | |
dc.contributor.author | Ning, Hongyan | |
dc.contributor.author | Allen, Norrina B. | |
dc.contributor.author | Siddique, Juned | |
dc.contributor.author | Carson, April P. | |
dc.contributor.author | Bancks, Michael P. | |
dc.contributor.author | Lewis, Cora E. | |
dc.contributor.author | Carr, John Jeffrey | |
dc.contributor.author | Speliotes, Elizabeth | |
dc.contributor.author | Terrault, Norah A. | |
dc.contributor.author | Rinella, Mary E. | |
dc.contributor.author | Vos, Miriam B. | |
dc.contributor.author | Lloyd‐jones, Donald M. | |
dc.date.accessioned | 2018-11-20T15:34:40Z | |
dc.date.available | 2020-01-06T16:40:59Z | en |
dc.date.issued | 2018-11 | |
dc.identifier.citation | VanWagner, Lisa B.; Ning, Hongyan; Allen, Norrina B.; Siddique, Juned; Carson, April P.; Bancks, Michael P.; Lewis, Cora E.; Carr, John Jeffrey; Speliotes, Elizabeth; Terrault, Norah A.; Rinella, Mary E.; Vos, Miriam B.; Lloyd‐jones, Donald M. (2018). "Twentyâ fiveâ year trajectories of insulin resistance and pancreatic βâ cell response and diabetes risk in nonalcoholic fatty liver disease." Liver International 38(11): 2069-2081. | |
dc.identifier.issn | 1478-3223 | |
dc.identifier.issn | 1478-3231 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/146427 | |
dc.description.abstract | Background & AimsInsulin resistance is a risk marker for nonâ alcoholic fatty liver disease, and a risk factor for liver disease progression. We assessed temporal trajectories of insulin resistance and βâ cell response to serum glucose concentration throughout adulthood and their association with diabetes risk in nonâ alcoholic fatty liver disease.MethodsThree thousand and sixty participants from Coronary Artery Risk Development in Young Adults, a prospective biâ racial cohort of adults age 18â 30 years at baseline (1985â 1986; Y0) who completed up to 5 exams over 25 years and had fasting insulin and glucose measurement were included. At Y25 (2010â 2011), nonâ alcoholic fatty liver disease was assessed by noncontrast computed tomography after exclusion of other liver fat causes. Latent mixture modelling identified 25â year trajectories in homeostatic model assessment insulin resistance and βâ cell response homeostatic model assessmentâ β.ResultsThree distinct trajectories were identified, separately, for homeostatic model assessment insulin resistance (lowâ stable [47%]; moderateâ increasing [42%]; and highâ increasing [12%]) and homeostatic model assessmentâ β (lowâ decreasing [16%]; moderateâ decreasing [63%]; and highâ decreasing [21%]). Y25 nonâ alcoholic fatty liver disease prevalence was 24.5%. Among nonâ alcoholic fatty liver disease, highâ increasing homeostatic model assessment insulin resistance (referent: lowâ stable) was associated with greater prevalent (OR 95% CI = 8.0, 2.0â 31.9) and incident (OR = 10.5, 2.6â 32.8) diabetes after multivariable adjustment including Y0 or Y25 homeostatic model assessment insulin resistance. In contrast, nonâ alcoholic fatty liver disease participants with lowâ decreasing homeostatic model assessmentâ β (referent: highâ decreasing) had the highest odds of prevalent (OR = 14.1, 3.9â 50.9) and incident (OR = 10.3, 2.7â 39.3) diabetes.ConclusionTrajectories of insulin resistance and βâ cell response during young and middle adulthood are robustly associated with diabetes risk in nonâ alcoholic fatty liver disease. Thus, how persons with nonâ alcoholic fatty liver disease develop resistance to insulin provides important information about risk of diabetes in midlife above and beyond degree of insulin resistance at the time of nonâ alcoholic fatty liver disease assessment. | |
dc.publisher | Wiley Periodicals, Inc. | |
dc.subject.other | nonâ alcoholic fatty liver disease | |
dc.subject.other | nonâ alcoholic steatohepatitis | |
dc.subject.other | obesity | |
dc.subject.other | coronary artery risk development in young adults | |
dc.title | Twentyâ fiveâ year trajectories of insulin resistance and pancreatic βâ cell response and diabetes risk in nonalcoholic fatty liver disease | |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | https://deepblue.lib.umich.edu/bitstream/2027.42/146427/1/liv13747_am.pdf | |
dc.description.bitstreamurl | https://deepblue.lib.umich.edu/bitstream/2027.42/146427/2/liv13747.pdf | |
dc.identifier.doi | 10.1111/liv.13747 | |
dc.identifier.source | Liver International | |
dc.identifier.citedreference | Allen NB, Siddique J, Wilkins JT, et al. Blood pressure trajectories in early adulthood and subclinical atherosclerosis in middle age. JAMA. 2014; 311: 490 â 497. | |
dc.identifier.citedreference | Gaggini M, Morelli M, Buzzigoli E, DeFronzo RA, Bugianesi E, Gastaldelli A. Nonâ alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients. 2013; 5: 1544 â 1560. | |
dc.identifier.citedreference | Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013; 10: 330 â 344. | |
dc.identifier.citedreference | Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015; 62 ( 1 Suppl ): S47 â S64. | |
dc.identifier.citedreference | Rakoski MO, Singal AG, Rogers MA, Conjeevaram H. Metaâ analysis: insulin sensitizers for the treatment of nonâ alcoholic steatohepatitis. Aliment Pharmacol Ther. 2010; 32: 1211 â 1221. | |
dc.identifier.citedreference | Mazzotti A, Caletti MT, Marchignoli F, Forlani G, Marchesini G. Which treatment for type 2 diabetes associated with nonâ alcoholic fatty liver disease? Dig Liver Dis. 2017; 49: 235 â 240. | |
dc.identifier.citedreference | European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASLâ EASDâ EASO Clinical Practice Guidelines for the management of nonâ alcoholic fatty liver disease. J Hepatol. 2016; 64: 1388 â 1402. | |
dc.identifier.citedreference | Siddiqui MS, Cheang KL, Luketic VA, et al. Nonalcoholic Steatohepatitis (NASH) Is Associated with a Decline in Pancreatic Beta Cell (betaâ Cell) Function. Dig Dis Sci. 2015; 60: 2529 â 2537. | |
dc.identifier.citedreference | Bedogni G, Gastaldelli A, Tiribelli C, et al. Relationship between glucose metabolism and nonâ alcoholic fatty liver disease severity in morbidly obese women. J Endocrinol Invest. 2014; 37: 739 â 744. | |
dc.identifier.citedreference | Rijkelijkhuizen JM, Doesburg T, Girman CJ, et al. Hepatic fat is not associated with betaâ cell function or postprandial free fatty acid response. Metabolism. 2009; 58: 196 â 203. | |
dc.identifier.citedreference | Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004; 27: 1487 â 1495. | |
dc.identifier.citedreference | Friedman GD, Cutter GR, Donahue RP, et al. CARDIA: study design, recruitment, and some characteristics of the examined subjects. J Clin Epidemiol. 1988; 41: 1105 â 1116. | |
dc.identifier.citedreference | Bergman RN, Ader M, Huecking K, Van Citters G. Accurate assessment of betaâ cell function: the hyperbolic correction. Diabetes. 2002; 51 ( Suppl 1 ): S212 â S220. | |
dc.identifier.citedreference | Parker ED, Schmitz KH, Jacobs DR, Dengel DR, Schreiner PJ. Physical activity in young adults and incident hypertension over 15Â years of followâ up: the CARDIA study. Am J Public Health. 2007; 97: 703 â 709. | |
dc.identifier.citedreference | VanWagner LB, Ning H, Lewis CE, et al. Associations between nonalcoholic fatty liver disease and subclinical atherosclerosis in middleâ aged adults: The Coronary Artery Risk Development in Young Adults Study. Atherosclerosis. 2014; 235: 599 â 605. | |
dc.identifier.citedreference | Kodama Y, Ng CS, Wu TT, et al. Comparison of CT methods for determining the fat content of the liver. AJR Am J Roentgenol. 2007; 188: 1307 â 1312. | |
dc.identifier.citedreference | Marchesini G, Marzocchi R. Metabolic syndrome and NASH. Clin Liver Dis. 2007; 11: 105 â 117, ix. | |
dc.identifier.citedreference | Nagin DS, Odgers CL. Groupâ based trajectory modeling (nearly) two decades later. J Quant Criminol. 2010; 26: 445 â 453. | |
dc.identifier.citedreference | Gutierrezâ Buey G, Nunezâ Cordoba JM, Llaveroâ Valero M, Gargallo J, Salvador J, Escalada J. Is HOMAâ IR a potential screening test for nonâ alcoholic fatty liver disease in adults with type 2 diabetes? Eur J Intern Med. 2017; 41: 74 â 78. | |
dc.identifier.citedreference | Tripathy D, Almgren P, Tuomi T, Groop L. Contribution of insulinâ stimulated glucose uptake and basal hepatic insulin sensitivity to surrogate measures of insulin sensitivity. Diabetes Care. 2004; 27: 2204 â 2210. | |
dc.identifier.citedreference | Duckworth WC, Kitabchi AE. Insulin metabolism and degradation. Endocr Rev. 1981; 2: 210 â 233. | |
dc.identifier.citedreference | Bril F, Barb D, Portilloâ Sanchez P, et al. Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease. Hepatology. 2017; 65: 1132 â 1144. | |
dc.identifier.citedreference | Fabbrini E, Magkos F. Hepatic steatosis as a marker of metabolic dysfunction. Nutrients. 2015; 7: 4995 â 5019. | |
dc.identifier.citedreference | Pagano G, Pacini G, Musso G, et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology. 2002; 35: 367 â 372. | |
dc.identifier.citedreference | Kahn SE. The relative contributions of insulin resistance and betaâ cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia. 2003; 46: 3 â 19. | |
dc.identifier.citedreference | Musso G, Gambino R, Cassader M, Pagano G. Metaâ analysis: natural history of nonâ alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of nonâ invasive tests for liver disease severity. Ann Med. 2011; 43: 617 â 649. | |
dc.identifier.citedreference | Blais P, Husain N, Kramer JR, Kowalkowski M, Elâ Serag H, Kanwal F. Nonalcoholic fatty liver disease is underrecognized in the primary care setting. Am J Gastroenterol. 2015; 110: 10 â 14. | |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.